Clinical Study

Incb57643-103- A Phase 1, Open-Label, Safety And Tolerability Study Of Incb057643 In Participants With Myelofibrosis

Posted Date: Jan 18, 2021

  • Investigator: Emily Curran
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy for participants with relapsed or refractory myelofibrosis. Safety will be measured by tracking the number of treatment emergent adverse events.


To Be Eligible: Must Have Relapsed Or Refractory Primary Myelofibrosis (Mf) Or Secondary Mfs (Post-Polycythemia Vera Mf, Post-Essential Thrombocythemia Mf), Must Not Be A Candidate For Potentially Curative Therapy, Including Hematopoietic Stem-Cell Transplantation, No Prior Receipt Of Any Bet Inhibitor, No Use Of Any Potent Cyp3a4 Inhibitors Or Inducers Within 14 Days, No History Of Bleeding Disorder


Myelofibrosis, Incb057643

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.